Catalyst
Slingshot members are tracking this event:
The FDA set a target review date of September 30, 2016 for a decision on Orkambi sNDA in Homozygous patients aged 6-11
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 28, 2016
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=991350
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Orkambi, Snda, Homozygous Patients
